Sclerosis

#Mediar Therapeutics #Qureight #Sclerosis

Mediar selects Qureight to support systemic sclerosis trial 

Biotechnology company Mediar Therapeutics has enlisted the support of CRO Qureight in the Phase II trial of a treatment for systemic sclerosis.  Qureight’s AI 3D quantitative imaging analytics platform and services will be used to support Mediar’s Phase II EncompaSSc clinical trial. The trial will evaluate MTX-474, a monoclonal antibody therapeutic for people with diffuse cutaneous systemic… Read More

#Business & Investment #News

Fibrous dysplasia disease
#Certa Therapeutics #FDA #Scleroderma #Sclerosis

Scleroderma drug gets fast-tracked in the US 

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Certa Therapeutics’ investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma).  The Fast Track Designation was granted based on results of a Phase II study which indicated that treatment of scleroderma patients… Read More

#News #Regulatory

#Clinical trials #Drug development #Drug discovery #Research #Sclerosis

Gesynta Pharma announces significant progress across new drug candidate

Gesynta Pharma has announced that an IND (Investigational New Drug Application) has been submitted to the U.S. Food & Drug Administration (FDA) for its oral drug candidate GS-248 in patients with systemic sclerosis. Concurrently, more than half of the patients in the ongoing Phase II study in four countries across… Read More

#News